A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell TherapyOtis
With the marketplace flush with Chimeric antigen receptor (CAR) T-cell therapies to treat relapsed/refractory large B-cell lymphoma (LBCL), one of the key clinical and economic differentiators may be the risk of cytokine release syndrome (CRS) and neurological events (NE). Our recent publication aimed to focus solely on this key feature of treatment with the aim of estimating the total cost of CRS and NE management among patients with relapsed/refractory LBCL treated with lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), or tisagenlecleucel (tisa-cel) in 3rd line and later-line settings. Based on clinical trial rates, liso-cel had the lowest weighted average CRS and NE costs (on average ~$20,000-$30,000 lower than comparators) per treated patient compared with axi-cel and tisa-cel.
Citation: Badaracco J, Gitlin M, Keating SJ. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy. Transplant Cell Ther. 2022 Oct 19:S2666-6367(22)01704-3. doi: 10.1016/j.jtct.2022.10.009. Epub ahead of print. PMID: 36272529.